Abramson Cancer Center hematologic malignancies’ clinicians and researchers have led the way nationally for years; both in the care of patients with hematologic malignancies (blood cancer) and in its research.
Today, there's more hope than ever for those who face a blood cancer diagnosis.
Penn’s program is one of the oldest and largest in the country. By putting our experience to work, we offer the best possible treatment outcomes.
Penn has one of the few Hematologic Malignancy (leukemia, lymphoma and myeloma) Research Programs in the country that is approved and funded by the National Cancer Institute. It is through this research program that Penn has made significant advances in improving bone marrow and stem cell transplants and the care of patients with blood cancer.
The knowledge gained through our research allows us to better care for those with blood cancers.
To learn about what sets us apart, visit:
By the age of seven, Tanya Zekovitch already understood what it was like to be a cancer patient after being treated for Ewing's Sarcoma, a rare form of bone cancer. So when she was diagnosed with Acute Myeloid Leukemia in the summer
Focus On Blood Cancers and Bone Marrow Transplant Video
A patient education video with testimonies from our patients, doctors and researchers. Find out more about programs, treatment, research and care that is unique to the Abramson Cancer Center.
Clinical trials are studies to find new ways to prevent, detect and treat cancer. The purpose of each clinical trial is to answer a specific question. Our physicians carefully design these studies to find new ways to improve care and quality of life ...